Additionally, to decrease the risk of off-target toxicity, cancer-testis antigens such as NY-ESO-1 and MAGE-A3, proteins normally restricted to fetal development or germ cells but aberrantly re-expressed in malignant cells, have been targeted, with immunization leading to durable immune responses in proof-of-concept studies (129, 130). The gene discussed is MAGEA3; the disease is cancer.